



Grunnlag for fastsettelse av grenseverdi

Grunnlagsdokument for
natriumazid (NaN_3)

Tittel: Grunnlag for fastsettelse av grenseverdi.
Grunnlagsdokument for natriumazid (NaN₃).

Utgitt av:
Arbeidstilsynet
Statens hus, 7468 Trondheim
Tlf: 73 19 97 00
Utgivelse: Desember 2014
Nettadresse: www.arbeidstilsynet.no

Dette dokumentet omhandler det toksikologiske grunnlaget og vurderinger, samt tekniske og økonomiske hensyn for fastsettelse av grenseverdi for natriumazid (NaN₃).



Innhold

| | |
|-----------------------------------------------------|-----------|
| Innhold | 3 |
| Forord | 4 |
| Innledning | 5 |
| 1. Stoffets identitet | 5 |
| 2. Grenseverdier | 5 |
| 2.1. Nåværende grenseverdi | 5 |
| 2.2. Grenseverdi fra EU | 5 |
| 2.3. Grenseverdier fra andre land og organisasjoner | 6 |
| 2.4. Stoffets klassifisering | 7 |
| 2.4.1. Merkeforskriften | 7 |
| 2.4.2. CLP | 7 |
| 3. Fysikalske og kjemiske data | 7 |
| 4. Toksikologiske data og helseeffekter | 8 |
| 4.1. Anbefaling fra SCOEL | 8 |
| 4.2. Kommentarer fra TEAN for natriumazid | 8 |
| 5. Bruk og eksponering | 9 |
| 5.1. Forekomst og bruk | 9 |
| 5.2. Opplysning fra Produktregistret | 9 |
| 5.3. Eksponering og måledokumentasjon | 9 |
| 5.3.1. EXPO-data | 9 |
| 5.3.2. Prøvetakings- og analysemetode | 9 |
| 6. Vurdering | 10 |
| 7. Konklusjon med forslag til ny grenseverdi | 10 |
| 8. Ny grenseverdi | 11 |
| 9. Referanser | 11 |
| Vedlegg 1: Anbefalinger fra SCOEL | 12 |



Forord

EU-rådets direktiv 98/24/EC (Vern av helse og sikkerhet til arbeidstakere mot risiko i forbindelse med kjemiske agenser på arbeidsplassen) av 7. april 1998 stiller krav om at EU-kommisjonen skal legge frem forslag til indikative grenseverdier for eksponering av visse kjemikalier som medlemslandene må innføre på nasjonalt nivå. De nasjonale verdiene kan være høyere enn de som står oppført i direktivet, dersom et medlemsland mener at det er nødvendig av tekniske og/eller økonomiske hensyn, men landene bør nærme seg den indikative verdien. Direktivet stiller krav om at indikative grenseverdier vedtas gjennom kommisjonsdirektiv. I Norge ble de indikative grenseverdiene innført som veiledende administrative normer.

Nye Arbeidsmiljøforskrifter trådte i kraft 1.1.2013. Blant disse var forskrift om tiltaksverdier og grenseverdier for fysiske og kjemiske faktorer i arbeidsmiljøet samt smitterisikogrupper for biologiske faktorer (forskrift om tiltaks- og grenseverdier). De veiledende administrative normene ble forskriftsfestet og fikk betegnelsen tiltaksverdier.

I 2015 ble begrepet «grenseverdi» for kjemikalier presisert og begrepet «tiltaksverdi» for kjemikalier ble opphevet i forskrift om tiltaks- og grenseverdier. I vedlegg 1 til forskriften ble det innført en tydeliggjøring av anmerkningene.

I hovedsak er grunnlaget for fastsetting av grenseverdi av stoffene i denne revisjonen utarbeidet i forbindelse med implementering av kommisjonsdirektiv 2000/39/EC. Direktivet ble implementert uten at grunnlaget for at Norge hadde en høyere verdi ble begrunnet. For flere av disse har EU også foreslått en korttidsverdi som Norge manglet regelverk for å kunne innføre på det tidspunktet.

Arbeidstilsynet har ansvaret for revisjonsprosessen og utarbeidelse av grunnlagsdokumenter for stoffene som blir vurdert. Det toksikologiske grunnlaget for stoffene i denne revisjonen baserer seg på kriteriedokumenter fra EUs vitenskapskomité for fastsettelse av grenseverdier, Scientific Committee for Occupational Exposure Limits (SCOEL). SCOEL utarbeider de vitenskapelige vurderingene som danner grunnlaget for anbefalinger til helsebaserte grenseverdier, og disse legges fram for kommisjonen.

Statens arbeidsmiljøinstitutt (STAMI) ved Toksikologisk ekspertgruppe for administrative normer (TEAN) bidrar med faglige vurderinger i dette arbeidet. TEAN vurderer og evaluerer de aktuelle SCOEL dokumentene, presiserer kritiske effekter og vurderer behov for korttidsverdier ut i fra den foreliggende dokumentasjonen. Videre søker og evaluerer TEAN nyere litteratur etter utgivelsen av dokumentet. TEAN bruker kriteriene gitt i SCOEL's metododokument, "Methodology for the derivation of occupational exposure limits: Key documentation (version 6)". Dette er inkludert i TEANs Metododokument del B (Prosedyre for utarbeidelse av toksikologiske vurderinger for stoffer som skal implementeres i den norske administrative norm liste etter direktiv fra EU-kommisjonen) utarbeidet for denne revisjonen.

Informasjon om bruk og eksponering i Norge innhentes fra Produktregisteret, EXPO databasen ved STAMI og eventuelle tilgjengelige måledata fra virksomheter/næringer.

Beslutningsprosessen skjer gjennom drøftingsmøter der Arbeidstilsynet, Næringslivets hovedorganisasjon/Norsk Industri og Landsorganisasjonen deltar, orienteringsmøter og høring. Konklusjonene fra høringen med forskriftsendringer og nye grenseverdier forelegges Arbeids- og sosialdepartementet som tar den endelige beslutningen.



Innledning


Dette grunnlagsdokumentet omhandler vurderingsgrunnlaget for fastsettelse av grenseverdi for natriumazid. Innholdet bygger på anbefalinger for dette stoffet fra Scientific Committee on Occupational Exposure Limits (SCOEL) i EU (vedlegg 1) og kommentarer fra TEAN.

1. Stoffets identitet

Stoffets navn, kjemiske symbol, stoffets identifikasjonsnummer i Chemical Abstract Service (CAS-nr.), European Inventory of Existing Commercial chemical Substances (EINECS-nr. el. EC-nr.) og indekseringsnummer (Indeks-nr.) er gitt i tabell 1. Figur 1 viser strukturformel av stoffet.

Tabell 1. Stoffets navn og identitet.

| | |
|---------------|------------------|
| Navn | Natriumazid |
| Molekylformel | NaN ₃ |
| Synonym | Natriumsalt |
| CAS-nr. | 26628-22-8 |
| EC-nr. | 247-852-1 |
| Indeks-nr. | 011-004-00-7 |



Figur 1 Strukturformel av natriumazid, NaN₃.

2. Grenseverdier

2.1. Nåværende grenseverdi

Grenseverdi (Forskrift om Tiltaks- og grenseverdi, best. nr. 704) for natriumazid i Norge er:

0,3 mg/m³, anmerkning T (takverdi) og H (kjemikalier som kan tas opp igjennom huden).

2.2. Grenseverdi fra EU

I direktiv 2000/39/EC foreslås:

IOELV (Indicative Occupational Exposure Limit Value): 0,1mg/m³

STEL (Short Term Exposure Limit, 15 min): 0,3 mg/m³, med anmerkning «skin».



Den europeiske vitenskapskomiteen, SCOEL foreslår for natriumazid i sitt kriteriedokument fra 1992:

8-timers TWA: 0,1 mg/m³.

2.3. Grenseverdier fra andre land og organisasjoner

Nåværende grenseverdier for natriumazid fra andre land og organisasjoner er gitt i tabell 2 nedenfor.

Tabell 2. Grenseverdier for natriumazid fra andre land og organisasjoner.

| Land/organisasjon | Kilde | Grenseverdi | Anmerkning |
|------------------------|--------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Sverige | Arbetsmiljöverkets föreskrifter och allmänna råd om hygieniska gränsvärden, AFS 2011:18 ¹ | Ingen grenseverdi. | Note 21: III: Anbefaler EU grenseverdi og anmerkning: se avsnitt 2.2. |
| Danmark | At-vejledning, stoffer og materialer - C.0.1, 2007 ² | 8-timers-verdi: 0,1 mg/m ³ | E (EF-grenseverdi) H (hudopptak) |
| Finland | HTP-värden 2012 ³ | 8-timers-verdi: 0,1 mg/m ³ Korttidsverdi (15 min): 0,3 mg/m ³ | hud |
| Storbritannia | EH40/2005 Workplace exposure limits ⁴ | 8-timers-verdi: 0,1 mg/m ³ Korttidsverdi (15 min): 0,3 mg/m ³ | Sk (hudopptak) |
| Nederland | The Social and Economic Council of the Netherlands (SER), Occupational exposure limits database ⁵ | 8-timers-verdi: 0,1 mg/m ³ Korttidsverdi (15 min): 0,3 mg/m ³ | H (hudopptak) |
| ACGIH, USA | ACGIH Guide to occupational Exposure Values, 2012 ⁶ | CEIL(C): 0,11* ppm, 0,29** mg/m ³ | C (takverdi) *som HN ₃ gass ** som NaN ₃ TLV A4: ikke klassifisert som human karsinogen |
| NIOSH, USA | ACGIH Guide to occupational Exposure Values, 2012 ⁶ | CEIL(C): 0,1* ppm, 0,3** mg/m ³ | C (takverdi) *som HN ₃ gass ** som NaN ₃ Skin TLV A4: ikke klassifisert som human karsinogen |
| DFG MAK | List of MAK and BAT Values 2013 ⁷ | 8-timers TWA: 0,2 mg/m ³ | I(2) (Overskridelsesfaktor) D (ingen tilgjengelige data for vurdering av embryo- eller fosterskade, eller tilgjengelige data ikke tilstrekkelig for klassifisering i en av gruppene A-C) |
| Tyskland, Myndighetene | BauA ⁸ | 8-timers-verdi: 0,2 mg/m ³ | EU (EU-verdi) |

¹ http://www.av.se/dokument/afs/afs2011_18.pdf



² <http://www.at.dk/~media/3FA26655715740ED84EA28EC1191FB62.ashx>

³ Social og h lsoverdsministeriet, HTP-v rden, Koncentrationer som befunnits skadlige, Publikationer 2012:06, Helsingfors, http://www.stm.fi/c/document_library/get_file?folderId=5197397&name=DLFE-19906.pdf

⁴ <http://www.hse.gov.uk/pubns/priced/ch40.pdf>

⁵ http://www.ser.nl/en/oel_database.aspx

⁶ Guide to occupational exposure values compiled by ACGIH, 2013.

⁷ Deutsche Forschungsgemeinschaft, List of MAK and BAT values 2013, Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area, report No. 49, 2013, Wiley-VCH, Tyskland.

⁸ http://www.baua.de/de/Themen-von-A-Z/Gefahrstoffe/TRGS/pdf/TRGS-900.pdf;jsessionid=EB7292E8B7DED5F0931D016EBF4ACF0B?_blob=publicationFile&v=7

2.4. Stoffets klassifisering

Forskrift om klassifisering, merking m.v. av farlige kjemikalier (merkeforskriften) blir erstattet av CLP (*Classification, Labelling and Packaging of substances and mixtures*) som er de nye reglene for klassifisering, merking og emballering av stoffer og stoffblandinger i EU. CLP vil gradvis fase ut merkeforskriften, og CLP og merkeforskriften vil gjelde parallelt fram til 1. juni 2015.

2.4.1. Merkeforskriften

Natriumazid er klassifisert i henhold til merkeforskriften med risikosetninger Xn: R22 «Farlig ved svelging»; Xi: R38 «Irriterer huden»; N: R50/53 «Meget giftig for vannlevende organismer, kan for rsake u nskede langtidsvirkninger i vannmilj et».

2.4.2. CLP

Natriumazid er klassifisert i henhold til reguleringen (EC) No 1272/2008 Annex VI. Natriumazid er klassifisert og merket med koder i henhold til fareklasse og kategori som gitt i Tabell 3 nedenfor.

Tabell 3. Fareklasser, farekategori, faresetninger, samt merkekoder for natriumazid.¹

| Fareklasse og farekategori | Merkekode | Faresetning |
|----------------------------------------|-----------|----------------------------------------------------|
| Akutt giftighet, farekategori 2* | H300 | D delig ved svelging |
| Farlig for vannmilj et, farekategori 1 | H400 | Meget giftig for liv i vann |
| Farlig for vannmilj et, farekategori 1 | H410 | Meget giftig, med langtidsvirkning, for liv i vann |

¹ <http://esis.jrc.ec.europa.eu/clp/ghs/search.php>

*Koden til farepliktogrammene og H-setningene skal ikke angis ved merking.

3. Fysikalske og kjemiske data

Natriumazid er en uorganisk forbindelse med formel NaN_3 , og stoffet foreligger som et fargel st krystallinsk fint pulver. Natriumazid er litt l selig i etanol og ul selig i dietyler (Handbook of Chemistry and Physics, 2013-2014). For fysikalske og kjemiske data for natriumazid vises det til tabell 4 nedenfor.



Tabell 4. Fysikalske og kjemiske data for natriumazid.

| | |
|----------------------------------------------------------|---------------------------------|
| Molekylformel | NaN₃ |
| Molekylvekt (u) | 65,01 ¹ |
| Fysisk tilstand (romtemperatur) | Fast stoff (krystallinsk) |
| Smeltepunkt (°C) | - |
| Kokepunkt (°C) | 300 (dekomponerer) ² |
| Tetthet (g/cm³) | 1,846 ² |
| Løselighet (20 °C) (g/100 g kaldt H₂O) | 40,8 ² |
| Gravitasjon (20 °C) (g/cm³) | 1,846 ¹ |
| Omregningsfaktor (20 °C, 101 kPa) | Ikke tilgjengelig ¹ |

¹SCOEL, 2009.

²W.M. Haynes (sjefeditor), *Handbook of Chemistry and Physics*, 94. ed., 2013-2014.

4. Toksikologiske data og helseeffekter

Vurdering av toksikologiske data og helseeffekter av natriumazid er angitt i SCOEL dokumentet på engelsk i vedlegg 1, og i kommentarer fra TEAN er gitt i kapittel 4.2.

4.1. Anbefaling fra SCOEL

Anbefaling fra SCOEL er vedlagt (vedlegg 1). Dokumentet påpeker at data på eksponeringer hos dyr og mennesker er svært begrenset.

4.2. Kommentarer fra TEAN for natriumazid

SCOEL's kriteriedokument for natriumazid er fra 2009 og er en oppdatering av dokumentet laget tidlig på 1990-tallet. Siste litteraturreferanse er fra 2008. Det ble søkt etter nyere dokumentasjon og annen vitenskapelig litteratur for stoffet i litteraturløpene PubMed, Toxline, Web Of Knowledge og Google Scholar for perioden 2009 og fram til i dag. Litteraturen beskriver flere humane tilfeller av forgiftninger med natriumazid, men det ble ikke funnet vitenskapelige artikler eller andre dokumenter som er relevant for bestemmelse av grenseverdier/tidligere tiltaksverdier.

Som SCOEL beskriver i sitt dokument, betraktes de kritiske systemiske effektene å være blodtrykksfall og effekter på sentralnervesystemet og at disse er relatert til den cytotoxiske effekten av natriumazid og dets metabolitter. Disse effektene inntreffer både ved akutt eksponering og er de sentrale effektene ved gjentatt eksponering for natriumazid. Kunnskapene om andre helseskader som resultat av kronisk eksponering er imidlertid mangelfulle. En rekke mer subjektive symptomer, som hodepine, hjertebank, åndenød, svimmelhet og uklart syn, er beskrevet hos personer som jobber med NaN₃. Dette er symptomer som trolig er mer vanlige enn signifikant blodtrykksfall, og kan være (forbigående) effekter av mer kortvarige, tilstrekkelig høye eksponeringer.

Konklusjon

Det foreligger ikke nyere opplysninger som skulle tilsi at de vurderingene SCOEL gjør angående 8-timers grenseverdi bør endres.



I motsetning til SCOEL mener TEAN at det er behov for korttidsverdi for å beskytte mot raskt inntreffende blodtrykksfall, effekter på sentralnervesystemet og vanlige subjektive symptomer knyttet til korttidseksponeringer.

5. Bruk og eksponering

5.1. Forekomst og bruk

Natriumazid blir brukt i organiske synteser, i produksjon av eksplosiver, som konserveringsmiddel i vandige laboratoriereagenser, som kjemikalie som generer gass i kollisjonspulver og som seteutløserne i jetfly.

Det blir årlig produsert 1 000 tonn av natriumazid i EEC.

5.2. Opplysning fra Produktregisteret

Det er funnet opplysninger om mengde og bruk av ett produkt av natriumazid i deklareringspliktige produkter etter års-oppdatering for 2013. På grunn av sikkerhetsbestemmelsene i Produktregisteret kan vi ikke gi eksakte opplysninger om hvilke bransjer og til hvilket produkt natriumazid brukes.

5.3. Eksponering og måledokumentasjon

5.3.1. EXPO-data

Det finnes ingen rapporterte målinger av natriumazid i STAMIs eksponeringsdatabase EXPO.

5.3.2. Prøvetakings- og analysemetode

I tabell 5 er anbefalt metode for prøvetaking og analyser av natriumazid presentert.

Tabell 5. Anbefalt metode for prøvetaking og analyse av natriumazid.

| Prøvetakingsmetode | Analysemetode | Referanse |
|-------------------------------------------|-----------------------|-------------------------------|
| Filterkassett og adsorbentør ¹ | Ionekromatografi (IC) | OSHA metode 7903 ² |

¹Oppsamling på kombinert prøvetaker; Filterkassett med 37 mm PVC (5 µm) filter og adsorbentør med NaOH impregnert silikagel adsorbent (SKC part. no 226-55) i serie.

²OSHA metode: <https://www.osha.gov/dts/sltc/methods/inorganic/id211/id211.html>

6. Vurdering

Det finnes ingen nyere litteratur (vitenskapelige artikler og dokumenter), enn de som er tatt med i kriteriedokumentet fra SCOEL (2009), som er relevant for bestemmelse av grenseverdi for natriumazid.

Basert på eksisterende inhalasjonsdata og blodtrykksfall hos en gruppe arbeidere er en LOAL beregnet til $0,3 \text{ mg/m}^3$ og for akutte episoder er LOAEL beregnet til $0,5 \text{ mg/m}^3$, som rapportert i kriteriedokumentet (SCOEL, 2009). Den vitenskapelige dokumentasjonen som foreligger i kriteriedokumentet for natriumazid anses således som tilstrekkelige for å kunne foreslå en helsebasert 8-timers grenseverdi (OEL). Den anbefalte grenseverdien/tidligere tiltaksverdien vil også beskytte mot irriterende effekt fra syreløsning av natriumazid.

Akutt toksisitet hos mennesker skyldes forgiftninger som et resultat av ulykker eller forsettlig inntak av natriumazid. SCOEL vurderer kritisk systemisk effekt å være blodtrykksfall, effekter på sentralnervesystemet, og subjektive symptomer (hodepine, svette, åndenød, svimmelhet, høy puls og uklart syn), og at disse effektene er relaterte til den cytotoxiske effekten av natriumazid og dens metabolitter. Inntak av doser på $0,65\text{-}1,35 \text{ mg}$ ($0,01\text{-}0,02 \text{ mg/kg}$) produserer øyeblikkelig et blodtrykksfall med varighet 10-15 minutter. For å beskytte mot raskt inntreffende blodtrykksfall, effekter på sentralnervesystemet og vanlige subjektive symptomer knyttet til korttidseksponering, anses dette som tilstrekkelig grunnlag for å fastsette en grenseverdi for korttidseksponering (STEL).

Den vitenskapelige dokumentasjonen i kriteriedokumentet (SCOEL, 2009) rapporterer ikke tilstrekkelig at hudopptak er mulig ved å bli eksponert for natriumazid i pulverform. På bakgrunn av denne dokumentasjonen tillegges ikke natriumazid anmerkningen H.

På grunn av manglende måledata fra berørt industri og virksomheter, er det ikke mulig å foreta tekniske og økonomiske vurderinger og konsekvenser av en revidering av grenseverdien/tidligere tiltaksverdien, men ut fra at stoffet brukes i svært begrenset grad i Norge forventes de negative konsekvenser av forslag til ny grenseverdi å være begrenset. Forslag til grenseverdi baserer seg derfor på en vurdering av de toksikologiske dataene.

7. Konklusjon med forslag til ny grenseverdi

På bakgrunn toksikologiske data og helseeffekter (kommentarer fra STAMI, TEAN i kapittel 4 og SCOEL kriteriedokument i vedlegg 1), og av vurderingen gitt i kapittel 6 foreslås at gjeldende grenseverdi for natriumazid endres.

På bakgrunn av tilgjengelig dokumentasjon foreslås følgende grenseverdi og korttidsverdi for natriumazid:

Grenseverdi (8-timer): $0,1 \text{ mg/m}^3$

Korttidsverdi (15 min): $0,3 \text{ mg/m}^3$

8. Ny grenseverdi

På grunnlag av drøftinger med partene og høringsuttalelser ble ny grenseverdi for natriumazid fastsatt til:

Grenseverdi (8-timer): 0,1 mg/m³

Korttidsverdi (15 min): 0,3 mg/m³

9. Referanser

Sutton WL. In: Patty FA, ed. Industrial hygiene and toxicology, 2nd rev. ed. Vol. 2. New York: Interscience Publisher, 1980, 220-8.

Referanser fra SCOEL kriteriedokument ligger vedlagt.

Vedlegg 1: Anbefalinger fra SCOEL





Recommendation from the Scientific Committee on Occupational Exposure Limits for sodium azide

SCOEL/SUM/51
September 2009



European Commission



Table of Contents

| | |
|---------------------------------------------------|----|
| 1. Occurrence/use and occupational exposure | 4 |
| 2. Health significance | 4 |
| 2.1. Toxicokinetics | 4 |
| 2.1.1. Human data | 4 |
| 2.1.2. Animal data | 4 |
| 2.1.3. Biological monitoring | 4 |
| 2.2. Acute toxicity | 4 |
| 2.2.1. Human data | 4 |
| 2.2.2. Animal data | 5 |
| 2.3. Irritation and corrosivity | 6 |
| 2.3.1. Human data | 6 |
| 2.3.2. Animal data | 7 |
| 2.4. Sensitisation | 7 |
| 2.5. Repeated dose toxicity | 7 |
| 2.5.1. Human data | 7 |
| 2.5.2. Animal data | 9 |
| 2.6. Genotoxicity | 10 |
| 2.6.1. In vitro | 10 |
| 2.6.2. In vivo | 10 |
| 2.7. Carcinogenicity | 11 |
| 2.7.1. Human data are not available | 11 |
| 2.7.2. Animal data | 11 |
| 2.8. Reproductive toxicity | 11 |
| Recommendations | 12 |
| References | 15 |





Recommendation from the Scientific Committee on Occupational Exposure Limits for sodium azide

8 hour TWA: 0.1 mg/m³


STEL (15 mins): -

Notation: -

BLV: -

Substance identification

Sodium azide:



Synonyms: Hydrazoic acid, sodium salt

EC No.: 247-852-1

Annex I Index No.: 011-004-00-7

EU Classification: T+; R28 - R32 - N; R50-53

CAS No.: 26628-22-8

MWt: 65.01

Conversion factor (20 °C, 101 kPa): not applicable

Physico-chemical properties

Sodium azide is a colourless, crystalline solid, manufactured as a very fine powder (Rippen HE at al., 1996).

Solubility in cold water: 40.17 g/100 g – in presence of water it is readily transformed to hydrazoic acid, the vapour of which may be present whenever the salt is handled. It is also soluble in ammonia but not in ether.

Sodium azide decomposes on heating, emitting toxic fumes (HSE, 2000).

Crystalline sodium azide is explosive.

Specific gravity of sodium azide: 1.846 g/cm³ at 20°C (ACGIH, 2001).





1. Occurrence/use and occupational exposure

Sodium azide is used in organic synthesis, in production of explosives, as a preservative in aqueous laboratory reagents, as a gas generating chemical in automobile air bags and seat ejectors of jet planes. It used to have limited use in the clinical management of hypertension in the 1950s. The production rate in the EU is in excess of 1000 tonnes per annum (HSE, 2000).

2. Health significance

2.1. Toxicokinetics

2.1.1. Human data

No quantitative data are available regarding the absorption, distribution, metabolism and elimination of sodium azide in humans.

It is reported to be quickly absorbed from the gastrointestinal tract. Hypotension developed within 45-60 sec after ingestion of 1.3 mg dose (Black et al., 1954).

The degree of skin penetration via undamaged skin is not clear. (Chang and Lamm, 2003).

2.1.2. Animal data

The azide anion appeared within 5 min in the plasma of rats following oral administration of 40 mg/kg sodium azide. After 24 h, no more azide could be detected in either plasma or tissue and only 7.9 µg were excreted in the 24 h urine. No sodium azide was detectable in the faeces or in exhaled air, suggesting a rapid and complete metabolism of this substance. (Lee, 1982).

The data on dermal absorption are contradictory (Bassendowska and Kowalski, 1961; Bassendowska et al., 1965; Potocar et al., 1985; see also acute dermal toxicity).

Sodium azide is reported to be quickly absorbed from injection sites and from the respiratory tract (Bassendowska, 1962; Reinhardt and Brittelli, 1981).

Sodium azide is mainly metabolised in the liver (Trochimowicz, 1990). The main metabolite in the liver is nitric oxide (Smith et al., 1991; Marquardt and Schäfer 1994). Sodium azide penetrates the blood-brain barrier (Smith et al., 1991). Azide anions may be metabolised to nitric oxide (NO) also in the CNS (HSE, 2000). In aqueous solution, it rapidly transforms into hydrazoic acid (CAS no. 7782-79-8), which may be responsible for the irritating effects attributed to sodium azide (Graham et al., 1948, cit. HSE, 2000; Haas and Marsh, 1970).

2.1.3 Biological monitoring

Biological monitoring is not in use, existing experimental blood tests are too insensitive to detect anticipated blood sodium azide levels (Rippen et al., 1996).

2.2. Acute toxicity

2.2.1. Human data

During clinical treatment, acute oral ingestion of 1.3 mg sodium azide rapidly (45-60 s.) decreased the blood pressure of hypertensive patients for 10-15 minutes, but had only minor effects on normotensive individuals. Therefore, a difference in the relative sensitivity





of normotensive and hypertensive individuals towards sodium azide is assumed (Black et al., 1954).

Most human acute toxicity data are coming from poisonings caused by accidental or intentional ingestion of sodium azide. The symptoms - sweating, headache, increased pulse rate, decreased blood pressure, blurred vision, faintness - were rapidly reversible after ingestion of 5 to 10 mg sodium azide (0.09 to 0.18 mg/kg) in one case, while in another case, the parameters reached normal levels again after 1 h of ingestion of 50-60 mg sodium azide. (Richardson et al., 1975).

In a fatal intentional case (no dose reported) oedema of the brain (severe) and the lungs (moderate), mild congestion of the abdominal organs, diffuse redness of the mucous membranes, fatty degeneration in the liver were also reported (Wollenek, 1989).

Acute hypotension, nausea, vomiting, and weakness were reported in two case studies, in which workers were exposed by inhalation to high concentrations of sodium azide dust (no figures given) during cleaning activities. Subsequently, both developed persistent reactive airway dysfunction syndrome (RADS - Weiss, 1996; see also section "irritation and corrosivity").

Massive exposure caused by a sodium azide canister explosion resulted in severe systemic toxicity and finally led to death (Pham et al., 2001). The exposed patient developed hypothermia, hypotension, bradycardia and a profound metabolic acidosis leading to death about 12 h after exposure.

(Chang and Lamm, 2003) cite 5 cases of dermal exposure in their review, of these one died and the other 4 showed no symptoms of intoxication. The one that died had 45% burns and presumably massive exposure via damaged skin.

2.2.2. Animal data

Inhalation exposure

Inhalation exposure of rats, mice, guinea pigs or cats to sodium azide at lethal concentrations caused hypothermia, convulsions, dyspnoea, palsy and hyperventilation followed by apnoea. At necropsy, both liver and kidneys were congested and the liver was bloody, while all other organs were anaemic (Fairhall et al., 1943; Hildebrandt and Schmidt, 1937).

Oral exposure

The substance is very toxic in acute oral studies, with an LD₅₀ of 27 mg/kg in mice (Graham, 1949). In rabbits, an oral dose of 3 to 10 mg/kg caused haematuria, tachycardia and a 40 to 60% reduction in blood pressure, which lasted at least 1 hour (Roth et al., 1956, cit in HSE, 2000).

Dermal exposure

No dermal LD₅₀ values are available in the scientific literature. Bassendowska and Kowalski (1961) concluded that the dermal lethal dose (LD) of sodium azide for rabbits is 18-21 mg/kg, based on a dermal irritation study, where a single rabbit, exposed to 60 mg substance via the skin, died after 6 hours. Another rabbit exposed to 40 mg (13 mg/kg), survived for 24 hours.

In a later study Bassendowska et al. (1965) established a 60 mg/kg dermal LD for rats.

In a skin irritation study Potocar et al. (1985) reported the death of 3 of the 6 rabbits in the test group for sodium azide. Four 3x3 cm patches with 0.5 g solid substance each





(altogether 2 g) were placed on the skin of each animal. Two patches were kept for 1 hour and two for 4 hours. The animals were followed for 7 days. The weight of the animals was 2-4 kg, so a 500-1000 mg/kg individual dose can be estimated, depending on the weight.

Unfortunately, no further data are given regarding the time of the deaths of the animals. As after 4 hours of exposure corrosion was detected on the skin, it cannot be excluded that the death of the animals was caused by penetration of sodium azide through the damaged skin.

Regarding dermal toxicity, however, it can be concluded from the study of Potocar et al. (1985), that 3 surviving animals were exposed to 500-1000 mg/kg sodium azide for 1 hour and then to half of that dose for three additional hours on their skins. These data do not support the low dermal LD value of 20 mg/kg for rabbit mentioned in the Bassendowska studies.

Other routes of exposure

After subcutaneous administration of sodium azide dissolved in water an LD50 of 45.1 mg/kg was established in rats and 23.06 mg/kg in mice (Bassendowska and Kowalski, 1961).

Intratracheal administration of sodium azide dissolved in water resulted in an LD50 of 47.5 mg/kg in rats (Bassendowska and Kowalski, 1961).

Analogous to humans, application of 0.1 mg sodium azide (i.v.) markedly decreased the blood pressure of hypertensive rats (from 180-200 mm Hg to 120-130 mm Hg) for a period of 30-45 minutes. However, it did not cause hypotensive effect on normotensive rats (Black et al., 1954).

2.3. Irritation and corrosivity

Sodium azide is not an irritant but is rapidly hydrolysed to hydrazoic acid in the acidic environment of mucous membranes and the tracheobronchial tree (Weiss, 1996).

2.3.1. Human data

10 workers potentially exposed to sodium azide and hydrazoic acid for 1 to 16 years complained of mild eye and nose irritation, but it is unclear what concentrations of sodium azide initiated these effects. Air concentrations of hydrazoic acid, measured over several days, were between 0.3 and 3.9 ppm (Graham et al., 1948, cit. HSE, 2000).

Among laboratory personnel working with sodium azide Haas and Marsh (1970) reported nasal irritation, attributed to hydrazoic acid vapour concentration of 0.5 ppm measured in the air.

Self-reported "red or irritated" eyes during the past 5 workdays occurred more frequently in 41 workers exposed to sodium azide (mean concentration in air: 0.23 mg/m³, range: 0 – 0.93 mg/m³, personal sampling, hydrazoic acid concentration was not measured) compared to 42 controls (85 % versus 41 %) (Miljours and Braun, 2003).

In the study of Trout et al. (1996) no irritation symptoms were reported among the 11 workers exposed up to 0.69 mg/m³ sodium azide concentration, with a simultaneously measured hydrazoic acid concentration up to 0.07 ppm in the air. The personal breathing zone sample results for the same workers were up to 1.7 mg/m³ sodium azide and up to 0.1 ppm hydrazoic acid.

In the Rippen et al. (1966) study eye or throat irritation symptoms occurred occasionally



during the 9 months follow up and do not seem to be in close connection with the sodium azide air concentrations measured. At the beginning of the study none of the 65 workers reported irritation symptoms (air sodium azide: 1-7.5 mg/m³, hydrazoic acid: 0.45 – 2.81 ppm). Three months later 4 cases of eye irritation and 1 case of sore throat were recorded (average air sodium azide below 1 mg/m³) and in the next two months again none irritation symptom was reported. At the end of the study (average air sodium azide below 0.5 mg/m³) only 1 case of eye irritation was recorded among the 65 workers. Persisting reactive airway dysfunction was reported in two case studies, in which workers were exposed by inhalation to high concentrations of sodium azide dust (no figures given) during cleaning activities (Weiss, 1996; see also section "acute toxicity – human data").

2.3.2. Animal data

No signs of dermal or conjunctival irritation appeared up to 10 hours (when the animals died) after the application of 4x10 mg sodium azide on 4 places (2 of them scarified) on the skin and simultaneously 20 mg into the conjunctival sac of 2 rabbits. (Bassendowska et al. 1961).

No sign of conjunctival irritation appeared after 24 hours when 20 mg sodium azide was applied into the conjunctival sac of a single rabbit. Another rabbit exposed to 60 mg substance via the skin, died after 6 hours without any sign of dermal irritation. A third rabbit exposed to 40 mg (13 mg/kg) sodium azide for 24 hours on the skin, showed local reaction (hyperemia, subepithelial exudation). (Bassendowska et al., 1961).

Dermal (semi-occlusive and occlusive) exposure to 0.5 g/patch solid sodium azide for 1 hour did not produce signs of local irritation in rabbits, whereas exposure for 4 hours was corrosive (Potokar et al., 1985). However, the authors concluded, that tests for corrosiveness should be carried out with an exposure time of 1 hour.

2.4. Sensitisation

No data were reported in HSE (2000) and none has been found since.

2.5. Repeated dose toxicity

2.5.1. Human data

Oral exposure

In a clinical study 9 normotensive individuals ingested 1.3 mg sodium azide three times/day (3.9 mg/day, or 0.056 mg/kg/day) for 10 days, without experiencing "sustained effect" on blood pressure (Black et al., 1954).

No evidence of kidney, heart and liver damage was detected by routine clinical examinations in 30 hypertensive patients treated with oral doses of 0.65 to 3.9 mg (up to approximately 0.056 mg/kg/day) sodium azide daily, for 5 days to "more than 2 years". The blood pressure of 25/30 patients decreased towards the normal level. Some of the patients developed increased sensitivity to sodium azide during repeated treatment, requiring the reduction of the dose (Black et al., 1954).

Inhalation exposure - occupational
Graham et al. (1948, zit. HSE 2000).



Detailed medical examinations were performed on 10 workers potentially exposed to sodium azide and hydrazoic acid for 1 to 16 years. No pathological changes were observed, although 'definite' hypotension was noted. The workers complained of headaches, palpitation, periods of weakness and mild eye and nose irritation, but it is unclear what concentrations initiated these effects

Trout et al. (1996).

11 workers were evaluated in a sodium azide production plant. The most often reported symptoms during the 6 months period prior to the evaluation were headaches (10/11), increased heart rate and palpitation (9/11), low blood pressure (9/11). For exposure assessment, at the time of the 24-hour evaluation survey 10 area samples (with results ranging from not detectable to 0.69 mg/m³ sodium azide) and 28 personal breathing zone (PBZ) samples were collected. Air sodium azide concentration of 7/28 PBZ samples exceeded the actual TLV of 0.3 mg/m³, the highest value being 1.7 mg/m³. During the simultaneous medical evaluation, 4/11 workers reported mild headaches. Two of them worked in the blending and packaging area, where the highest of all (1.7 mg/m³) PBZ air concentration was measured - for one of these workers 3 consecutive PBZ sample results measured within 3 hours were: trace, 0.31 and 0.43 mg/m³, respectively. Two of the workers with headache, however, were working in other areas, where PBZ sample results were 0 - 0.23 mg/m³. Blood pressure monitoring revealed one case of hypotensive episode occurring during the examination period, in the worker with PBZ air sample result of 1.7 mg/m³ sodium azide, but without complaints.

Rippen et al. (1996).

The occupational health and hygiene situation was evaluated in a sodium azide production plant, where the 65 employees had reported headaches, rapid pulses, the perception of lowered blood pressure and mental status changes, such as disorientation and near faints. Sodium azide air samples measured ranged from 0.20 - 5.87 mg/m³.

At the beginning of the study 1.0 - 7.5 mg/m³ sodium azide concentration was measured in the workplace air. Twelve of the 65 workers reported headache and none blood pressure changes or eye and throat irritation at this exposure level. Blood pressure surveillance system revealed that cross-shift decreases in the mean arterial blood pressures (-3.6 mmHg) did not reach the level regarded as significant change (NIOSH: 13.3 mmHg).

To assess the effect of possible higher short term azide exposure levels on the blood pressure, 12 short term (15 min) exposure air samples were collected for individual workers. Six of the measures exceeded 0.3 mg/m³ sodium azide (range: 0.36-1.49); the other 6 were less than 0.3 mg/m³ sodium azide (range: 0.01-0.15). The means of pre-exposure versus post exposure blood pressures and heart rates were not significantly different in the groups with exposure levels either below 0.3 mg/m³, or above 0.3 mg/m³. However, the mean pre-exposure blood pressure in the group with the higher exposure levels (>0.3 mg/m³) was significantly lower than that in the group with the lower exposure levels (<0.3 mg/m³).

After 5 months of monitoring, the hygienic measures introduced resulted in a constant decrease in the air sodium azide concentration. The number of workers reporting headache decreased from 12 to 1, while the cases with blood pressure changes reported varied between 0 and 3.

Miljours and Brown (2003).

The occupational neuropsychotoxicology of sodium azide was investigated annually, for



three years in 41 sodium azide exposed workers in a chemical production plant, compared to 42 unexposed ones working in the same plant. The duration of exposure of the workers varied between 5 and 30 years. In the past, the legal limit of 0.3 mg/m³ had often been exceeded. Personal air samples collected from each of the workers at the beginning of the survey indicated sodium azide concentrations ranging from 0 to 0.93 mg/m³, mean 0.23 mg/m³.

The systolic blood pressure was significantly lower in the exposed workers (125 mmHg versus 131 mmHg in the controls). Acute self-reported symptoms of toxicity during the past 5 workdays (headache, vertigo, nausea, fatigue, heart palpitation, eye irritation) were significantly more frequent in the exposed workers compared to the unexposed ones, however, the controls were affected quite often too. For example, 34 % of the controls had headache and 41 % of them had eye irritation versus 85 % in the exposed ones. These symptoms were reported with significant differences to controls, but with decreasing incidence in the second year survey. In the third year, only heart palpitations and eye irritation were reported significantly more often. Only one chronic symptom – tremor of the hands – was significantly increased for the exposed workers in year 1 (15 % versus none in the controls) and 3, but not in year 2. No explanation was offered for this difference by the authors. Nevertheless, the authors suggested to include a test for trembling in future studies on chronic sodium azide exposure. The results of psychological and neuropsychological tests did not differ between both groups, except for the impairments of mood in the exposed group

2.5.2. Animal data

Oral studies

NCI (1981) Study No. 5650.08 (cit. EPA):

90-day gavage (distilled water) study with rats (10/sex/group) exposed to 0, 1.25, 2.5, 5.0, 10 or 20 mg/kg/day sodium azide, 5 days/week. Nearly total mortality occurred at the 20 mg/kg dose, no deaths occurred at other doses. A trend of reduced weight gain was seen in the 10 mg/kg group. In females slightly elevated mean relative liver weights were measured in all dosage groups, with unknown statistical significance. Histopathology revealed lesions in the brain and lung of the high dose rats that died. Hunched postures were noted among males in the two highest dosage groups and females in the 20 mg/kg group.

NTP (1991) Study TR-389:

In a repeated oral dose study, rats received 0, 5, 10, 20, 40, 80, mg/kg/day sodium azide in water by gavage for 14 days (5 days/week). Deaths occurred with 20 mg/kg/day and above. Clinical findings of toxicity included lethargy and inactivity.

Oral administration of 0, 1.25, 2.5, 5.0, 10 or 20 mg/kg/day sodium azide in water by gavage for 13 weeks, resulted in statistically significant, but non-dose-related, increases in relative liver weights in female rats from all dose groups and 10% reduction of body weight in all treated groups. At the top dose, lethargy and laboured breathing preceded death, when necrosis in the cerebrum and thalamus, congestion, haemorrhage and oedema in the lungs were observed by microscopy. Blood pressure measurements were not made. Thus the LOAEL is 1.25 mg/kg and no NOAEL could be derived from these data.

In a 2-year carcinogenicity study male and female rats were treated with 0, 5, or 10



mg/kg/day sodium azide by gavage. The majority of rats given the 10 mg/kg dose showed clinical signs of systemic intoxication, but convulsions were recorded, coma and death occurred in both groups, given 5 or 10 mg/kg/day dose. Survival significantly decreased in the high dose groups. This was attributed to cardiovascular collapse secondary to brain necrosis. Histopathology revealed that sodium azide induced necrosis in the cerebrum and the thalamus of the brain both in male and female rats. The 2-year study demonstrated a cumulative toxicity from the long-term administration of sodium azide at doses that were not toxic in the short-term studies (NTP, 1991).

Parenteral studies

Rats receiving 0.4 mg/hour sodium azide by infusion for two weeks showed a 26-37% decrease in brain cytochrome oxidase activity in 22 different regions of the brain. The mesencephalic reticular formation and the central amygdala proved to be the most vulnerable. Also the correlative metabolic activity between hippocampal, amygdaloidal and cortical areas were deeply modified. The regional effects found were consistent with azide induced learning and memory dysfunctions (Cada et al., 1995).

In rats s.c. infusion of 1 mg/kg/h sodium azide selectively inhibited the mitochondrial cytochrome c oxidase activity in the brain, which became evident by 7th day of infusion and persisted for about 3 weeks (Bennett et al., 1996).

After 28 days of systemic administration of 0.86 mg/kg/h sodium azide Berndt et al. (2001) demonstrated a significant decrease of cytochrome oxidase activity in the brain and the skeletal muscle.

Similar neuropathological findings were reported by Mettler (1972 – cit Miljours and Braun, 2003) in sodium azide treated primates.

Lalonde et al. (1997) found adverse effects on motor activity and learning in mice injected with 6 or 12 mg/kg sodium azide.

In vitro and in vivo animal experiments demonstrated, that sodium azide impairs the cellular metabolism, by inhibiting phosphorylation (Bogucka and Wojtczak, 1996), glycogenesis (Robertson and Boyer, 1955), and oxidative enzymes like catalase (Nicholls, 1964), peroxidase (Smith and Wilcox, 1994) and cytochrome oxidase (Benneth et al., 1996).

2.6. Genotoxicity

2.6.1. In vitro

Sodium azide is mutagenic in vitro, producing gene mutations in bacteria (NTP, 1991) and mammalian cells (Jones et al., 1980). It induced sister chromatid exchanges, but did not produce chromosomal aberrations in two well-conducted studies using human lymphocytes and Chinese hamster ovary cells (NTP, 1991; Sander et al., 1978). Because of the specific metabolism of sodium azide in bacteria, mutagenicity in *Salmonella typhimurium* and in *Escherichia coli* is considered irrelevant for risk assessment (Greim, 2003).

2.6.2. In vivo

Sodium azide was not significantly mutagenic in *Drosophila melanogaster* and did not increase sex-linked recessive lethality (SLRL), (Sadiq et al., 2000). Slightly positive effects occurred in an other SLRL test on *D. melanogaster* (Kamra and Gollapudi, 1979) and



positive effects were observed in a dominant lethal test in the housefly (*Musca domestica*) (Thakur and Mann, 1981).

No studies on mammals are available to adequately assess germ cell effects (Greim, 2003).

2.7. Carcinogenicity

2.7.1. Human data are not available.

2.7.2. Animal data

In a well-conducted carcinogenicity study, no compound-related increases in tumour incidences were observed in rats treated with 0, 5 or 10 mg/kg/day sodium azide, 5d/w for 2 years (NTP, 1991).

Similarly there was no evidence of carcinogenicity in a 2-year study in which rats were fed 100 or 200 ppm sodium azide in the diet for 78 weeks (Weisburger et al., 1981).

2.8. Reproductive toxicity

Fertility

No human data on fertility are available

Animal data

Oral administration of 5 and 10 mg/kg sodium azide for a period of one year (5 d/w) did not cause significant changes in length and frequency of the oestrous cycle of female rats, but increased the number of cycles defined as "unclear" (NTP, 1991).

In the housefly (*Musca domestica*), sodium azide (1mg/ml diet) produced 72.3% infertility. Mating of dosed males with untreated females resulted in 33.1% infertility (Thakur and Mann, 1981).

Developmental toxicity

Human data on developmental toxicity are not available

Animal data

The effects of sodium azide on the foetus have been examined in Syrian hamsters following subcutaneous infusion via osmotic minipumps (Sana et al., 1990 a,b). Embryotoxicity was seen at dose levels that resulted in maternal toxicity (HSE, 2000).

Faqi et al., (2008) studied the developmental effects of sodium azide in rats. Oral doses of 0, 1, 5, or 17.5 mg/kg/day were administered from gestation day 6 through 19. The 17.5 mg/kg/day dose was reduced to 10 mg/kg/day from gestation days 10-12, due to maternal mortality. Reduced gestational body weight and fetal weight were recorded in the dams surviving the high dose treatment. No maternal deaths, clinical signs or body weight effects were seen at 1 or 5 mg/kg/day. No increase in the incidence of malformations and variations were observed at any of the doses evaluated. The NOAEL for maternal and developmental toxicity of sodium azide in rats was therefore considered to be 5 mg/kg/day.



Recommendations

The main route of exposure to sodium azide at the workplace is by inhalation as a fine powder. Critical systemic endpoints are the direct vasodilatory effect and effects on the central nervous system, related to the cytotoxic effects of sodium azide and/or metabolites.

Acute effects

Quantitative data on human occupational exposure to sodium azide are scarce. The typical symptoms reported by workers (headache, vertigo, nausea, fatigue, palpitation of the heart, faintness) generally regarded as secondary to hypotension. The available data on chronic occupational inhalation exposure suggest that some of these symptoms may be caused by the direct vasodilatory or CNS effects of sodium azide as they appeared at lower levels of exposure that caused hypotension. On the other hand, hypotensive episodes verified by blood pressure monitoring occurred without subjective symptoms.

In the study of Trout et al. (1996) headache occurred more often than hypotensive episodes, verified by blood pressure monitoring and at lower air concentration levels, that induced hypotension: 4/11 workers reported mild headaches, while blood pressure monitoring revealed only one case of hypotensive episode occurring during the examination period in an otherwise asymptomatic worker with personal breathing zone (PBZ) air sample result of 1.7 mg/m³ sodium azide. Two of the non-hypotensive workers with headache, were exposed to less than 0.23 mg/m³ sodium azide according to PBZ air sample results and for a third worker with headache 3 consecutive PBZ air sample results measured within 3 hours were: trace, 0.31 and 0.43 mg/m³, respectively.

Similarly, at the starting phase of the Rippen et al. (1996) study, when up to 7.5 mg/m³ sodium azide concentrations were measured, 12/65 cases of headache were reported, and no hypotension. With the gradual decrease of the average exposure level to less than 0.5 mg/m³, during the next 9 months the number of headaches decreased gradually to 1/65, while the occurrence of "blood pressure change" varied between 0 - 3/65 throughout the examination period. At the end of the study, when the lowest average air sodium azide concentration of 0.5 mg/m³ was measured, 2 cases of "blood pressure changes" were observed among 65 workers.

In the study of Miljours and Brown (2003) a surprisingly high frequency of headache was reported: both among the 42 unexposed controls (34 %) and among the 41 workers (85 %) exposed to a relatively low sodium azide concentration (range: 0 to 0.93 mg/m³), compared to the other studies. Hypotension was not reported at a mean exposure level of 0.23 mg/m³.

From the available occupational exposure studies no NOAEL or LOAEL can be derived for headache. From the Miljours and Brown (2003) study it is also obvious that headache is not specific symptom for sodium azide exposure, as it occurred in 41 % of the unexposed controls. (No control groups were in other studies.)

From the available data (Rippen et al., 1996) the LOAEL for the occurrence of hypotensive episodes can be estimated as 0.5 mg/m³.

Local effects

In the study of Trout et al. (1996) no irritation symptoms were reported among the 11 workers exposed up to 1.7 mg/m³ sodium azide concentration.

In the Rippen et al. (1966) study eye or throat irritation symptoms occurred occasionally



(0-5/65 cases) during the 9 months follow up and do not seem to be in close connection with the sodium azide air concentrations measured. At the end of the study (average air sodium azide at 0.5 mg/m³) only 1 case of eye irritation was recorded among the 65 workers.

The Miljours and Braun (2003) study is not in line with the previous two studies, reporting "red or irritated" eyes during the past 5 workdays in 85 % of the 41 workers, but also in 34 % of the 42 controls at a mean exposure level of 0.23 mg/m³, which makes the evaluation of these data difficult.

Repeated exposure

Regarding the effects of repeated sodium azide occupational exposure the following data are available:

In the Rippen et al. (1996) study the cross-shift changes of the mean arterial blood pressure were not significant, even at the beginning of the study (-3.8 mmHg), when the sodium azide exposure level was up to 7.5 mg/m³. However, with the decrease of the exposure level in the following months to 0.5 mg/m³, the cross shift change decreased significantly (-1.5 mmHg), compared to the earlier change. Also the group of 6 workers with personal breathing sample results above 0.3 mg/m³ sodium azide had lower mean pre-exposure blood pressure than the other 6 workers with results less than 0.3 mg/m³. This was attributed to their prior exposure at their activity area and individual work practices.

In the Miljours and Brown (2003) study the mean systolic blood pressure of the workers exposed to sodium azide for 5-30 years often at a level above 0.3 mg/m³, was significantly lower than that of the controls (125 versus 131 mmHg).

From the above data, in case of repeated occupational sodium azide exposure the LOAEL for slightly lower mean blood pressure at a group level can be estimated around 0.3 mg/m³.

In addition to the usual symptoms mentioned above, Miljours and Brown (2003) reported the tremor of the hands significantly more frequent in the sodium azide exposed workers at the beginning of the study (15 % versus 0 in the controls) and at the end of the third year, but not in the second year. It is also noteworthy, that this is the only study reporting tremor, despite tremor being an objective symptom easily detectable both by the observers and by the affected persons. The results of psychological and neuropsychological tests revealed impairments of mood, compared to the unexposed controls.

Other effects

Mutagenicity as observed in bacteria is not relevant for mammals, because of the specific metabolism of sodium azide in bacteria. Sodium azide was not significantly mutagenic in *Drosophila melanogaster* and did not or only slightly increased sex-linked recessive lethality. Positive effects were observed in a dominant lethal test in the housefly. No studies on mammals are available to adequately assess germ cell effects (Greim, 2003).

At concentrations of 5 and 10 mg/kg sodium azide there was no evidence of carcinogenicity in rats during a 2-year study.

The reproductive toxicity of this substance cannot be adequately assessed.

Developmental toxicity: the NOAEL for maternal and fetal toxic effects of sodium azide was found to be 5 mg/kg/day in rats treated on gestation days 6-19 by gavage; teratogenic effects were not observed at any of the doses administered, including a dose with severe maternal and fetal toxicity (Faqi et al., 2008).



Recommended OELs for sodium azide

Based on the available occupational inhalation data and the best possible estimation of LOAEL of 0.3 mg/m^3 for mean blood pressure decrease observed in workers at a group level, and a LOAEL of 0.5 mg/m^3 for the occurrence of acute hypotensive episodes, an 8-hour TWA of 0.1 mg/m^3 is recommended to prevent hypotension and the onset of acute symptoms.

The proposed OEL will also protect against the irritating effects of hydrazoic acid that may be present in the workplace air where sodium azide is handled.

The available dermal toxicity data are contradictory and are not sufficient to assign a "skin notation".

At the level recommended, no measurement difficulties are foreseen (HSE, 2000).



References

- ACGIH, American Conference of Governmental Industrial Hygienists, 2001
Sodium Azide
In: ACGIH, American Conference of Governmental Industrial Hygienists, Threshold Limit Values for Chemical Substances and Physical Agents and Biological Exposure Indices, 2004. Cincinnati, OH, 2001
- Bassendowska, E., Kowalski Z., 1961
Investigation of the toxicity of sodium azide. I. Experimental investigations of acute and subacute toxic activity
Medycyna Pracy, 12, 1962, 427-442
- Bassendowska, E., Kowalski, Z., Knobloch, K., Szendzikowski, S., 1965
Studies on the sodium azide toxicity. II. Chronic poisoning. 3. Absorption of sodium azide through the skin
Medycyna Pracy, 16, 1965, 187-199
- Bennett, M.C., Mlady, G.W., Kwon, Y.H., Rose, G.M., 1996
Chronic in vivo sodium azide infusion induces selective and stable inhibition of cytochrome c oxidase
J Neurochem, 66, 1996, 2606-2611
- Berndt, J.D., Callaway, N.L., Gonzalez-Lima, F., 2001
Effects of chronic sodium azide on brain and muscle cytochrome oxidase activity: a potential model to investigate environmental contribution to neurodegenerative diseases
J Toxicol Environ Health, 63 2001, 67-77
- Black, M.M., Zweifach, B.W., Speer, F.D., 1954
Comparison of hypotensive action of sodium azide in normotensive and hypertensive patients
Proceedings of the Society for Experimental Biology and Medicine, 85, 1954, 11-16
- Bogucka, K., Wojtzak, L., 1996
Effect of sodium azide on oxidation and phosphorylation process in rat liver mitochondria
Biochem Biophys Acta 122, 1996, 881-392
- Cada, A., Gonzalez-Lima, F., Rose, G.M., Bennett, M.C., 1995
Regional brain effects of sodium azide treatment on cytochrome oxidase activity: a quantitative histochemical study
Metab Brain Dis 10, 1995, 303-320
- Chang, S.; Lamm, S.H., 2003
Human health effects of sodium azide exposure: a literature review and analysis
International Journal of Toxicology, 22, 2003, 175-186
- Fairhall, L.T., Jenrette, W.V., Jones, S.W., Pritchard, E.A., 1943
The toxicity of lead azide
Public Health Report, 58, 1943, 607-617, cited in Greim, 2003
- Faqi, A. S., Richards, D., Hauwirth, J. W., Schroeder, R., 2008
Maternal and developmental toxicity of sodium azide in rats
Reg Toxicol Pharmacol 52, 2008, 158-162
- Graham, J.D.P., 1949
Actions of sodium azide
British Journal of Pharmacology, 4, 1949, 1-6, cited in Greim, 2003 and HSE, 2000





- Greim, H., 2003
Gesundheitsschädliche Arbeitsstoffe, Toxikologisch-arbeitsmedizinische Begründungen von MAK-Werten, Loseblattsammlung, 36. Lfg.
DFG, Deutsche Forschungsgemeinschaft, WILEY-VCH Verlag, Weinheim, 2003
- Haas, J.M., Marsh, W.M., 1970
Sodium azide: a potential hazard when used to eliminate interferences in the iodometric determination of sulfur
American Industrial Hygiene Association Journal, 31, 1970, 318-321
- Hildebrandt, F., Schmidt, K.F., 1937
Zur Toxikologie der Stickstoffwasserstoffsäure
Archiv für Experimentelle Pathologie und Pharmakologie, 187, 1937, 155-162, cited in Greim, 2003
- HSE, Health & Safety Executive, 2000
Consultation Document - European Commission Directive under the Chemical Agents Directive 98/24/EC to establish a First Consolidated List of Indicative Occupational Exposure Limit Values at European Community level
<http://www.hse.gov.uk/consult/condocs/cd156.htm>
- Hurst, E.W., 1942
Experimental demyelination of the central nervous system
Australian Journal of Biological Sciences, 20, 1942, 297-312, cited in Greim, 2003
- Jones, J.A., Starkey, J.R., Kleinhofs, A., 1980
Toxicity and mutagenicity of sodium azide in mammalian cell cultures
Mutation Research, 77, 293-299, cited in HSE, 2000
- Kamra, O.P., Gollapudi, B., 1979
Mutagenic effects of sodium azide in *Drosophila melanogaster*
Mutation Research, 66, 1979, 381-384, cited in Greim, 2003
- Lalonde, R., Joyal, C.C., Beatdin, S., 1997
Effects of sodium azide on motor activity, motor coordination and learning
Pharmacol Biochem Behav 56, 1997, 67-71
- Lee, E.W., 1982
Sodium azide: bioavailability and metabolism in rats
The Toxicologist, 2, 1982, 24, cited in Greim, 2003
- Marquardt, H., Schäfer, S.G., 1994
Lehrbuch der Toxikologie
BI Wissenschaftsverlag, 1994
- Mettler, F.A., 1972
Neuropathological effects of sodium azide administration in primates
Fed Proc 315, 1972, 1504-1507
- Mettler, F.A., Sax, D.S., 1972
Cerebellar cortical degeneration due to acute azide poisoning
Brain, 95, 1972, 505-516
- Miljours, S., Braun, C.M.J., 2003
A neuropsychotoxicological assessment of workers in a sodium azide production plant
International Archives of Occupational and Environmental Health, 76, 2003, 225-232
- Nicholls, P., 1964
The reactions of azide with the catalase and their significance
Biochem J, 90, 1964, 331-343
- NTP, National Toxicology Program, 1991
Toxicology and Carcinogenesis Studies of Sodium Azide in F344/N Rats and B6C3F1 Mice (Gavage Studies). TR 389
U.S. Department of Health and Human Services; Public Health Service, 1991



- Pham, T., Palmieri, T.L., Greenhalgh, D.G., 2001
Sodium azide burn: a case report
Journal of Burn Care & Rehabilitation, 22, 2001, 246-248
- Potokar, M., Grundler, O.J., Heusener, A., Jung, R., Mürmann, P., Schöbel, C., Suberg, H., Zechel, H.J., 1985
Studies on the design of animal tests for the corrosiveness of industrial chemicals
Food and Chemical Toxicology, 23, 615-617, cited in HSE, 2000 and Greim, 2003
- Reinhardt, C.F., Brittelli, M.R., 1981
Heterocyclic and miscellaneous nitrogen compounds: azides
In: Bingham, E., Cofrissen, B., Powell, C.H., *Patty's Industrial Hygiene and Toxicology*, Vol. 2, Interscience, New York, 2778-2784, cited in Chang and Lamm, 2003
- Richardson, S.G.N.; Giles, C.; Swan, C.H.J., 1975
Two cases of sodium azide poisoning by accidental ingestion of Isotin
Journal of Clinical Pathology, 28, 1975, 350-351
- Rippen, H.E., Lamm, S.H., Nicoll, P.G., Cummings, L., Howearth, G., Thayer, D., 1996
Occupational health data as a basis for process engineering changes: development of safe work environment in the sodium azide industry
Int Arch Occup Env Health 68 1996, 459-468
- Roth, F.E, Schurr, J., Moutis, E., Govier, W.M., 1956
Comparative hypotensive effects and toxicity of sodium azide and selected organic azides
Archives internationales de pharmacodynamie et de therapie, 108, 1956, 473-480, cited in HSE, 2000
- Sadiq, M.F., Owais, W.M., 2000
Mutagenicity of sodium azide and its metabolite azidoalanine in *Drosophila melanogaster*
Mutation Research, 469, 2000, 253-257
- Sana, T.R., Fenn, V.H., Smith, R.P., Kmszyna, R., Kmszyna, H.; Wilcox, D.E., 1990a
Embryotoxic effects of sodium azide infusions in the Syrian hamster
Fundamental and Applied Toxicology, 15, 754-759, cited in HSE, 2000
- Sana, T.R., Fenn, V.H., Smith, R.P., 1990b
Sodium azide (NaN₃) has weak teratogenic effects in the golden hamster
The Toxicologist, 10, 124, cited in HSE, 2000
- Sander, C., Nilan, R.A., Kleinhofsm A., Vig, B.K., 1978
Mutagenic and chromosome-breaking effects of azide in mammalian cell cultures
Mutation Research, 50, 67-75, cited in HSE, 2000
- Smith, R.P.; Louis, C.A.; Kruszyna, R.; Kruszyna, H., 1991
Acute neurotoxicity of sodium azide and nitric oxide
Fundamental and Applied Toxicology, 17, 1991, 120-127
- Thakur, J.N.; Mann, S.K., 1981
Infecundity and dominant lethal mutations induced in *Musca domestica* L. by sodium azide (NaN₃)
Experientia, 37, 1981, 824-825, cited in Greim, 2003
- Trochimowicz, H.J., 1990
Heterocyclic and miscellaneous nitrogen compounds: azides
In: Bingham, E.; Cofrissen, B.; Powell, C.H., *Patty's Industrial Hygiene and Toxicology*, Vol. 2, Interscience, New York, 3424-3428, cited in Chang and Lamm, 2003
- Trout, D., Esswein, E.J.; Hales, T., Brown, K., Solomon, G., Miller, M., 1996
Exposures and health effects: an evaluation of workers at a sodium azide production plant
American Journal of Industrial Medicine, 30, 1996, 343-350





- Weisburger, E.K., Ulland, B.M., Nam, J., Gart, J.J., Weisburger, J.H., 1981
Carcinogenicity tests of certain environmental and industrial chemicals
Journal of the National Cancer Institute, 67, 75-88, cited in HSE, 2000
- Weiss, J.S., 1996
Reactive airway dysfunction syndrome due to sodium azide inhalation
International Archives of Occupational and Environmental Health, 68, 1996, 469-471
- Williams, A.O., 1967
Studies on azide coeruleoplasmin and copper in relation to Wilson's Disease
British Journal of Experimental Pathology, 48, 180-187, cited in HSE, 2000
- Wollenek, G., 1989
Akute Vergiftungen durch Natriumazid
Wiener Klinische Wochenschrift, 101, 1989, 314-317





Annex 1: Acute animal toxicity and irritation data for Sodium azide

| Reference | Route | Species (n) | Dose | LD _{min} mg/kg | LD ₅₀ mg/kg | LD ₁₀₀ mg/kg |
|-----------------------------------------|---------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|-------------------------|
| Graham (1949) cit. HSE (2000). | oral | mice | | | 27 | |
| Bassendowska and Kowalski, (1961) | subcutan | rats (20) | 15-72 mg/kg in water | 44.5 | 45.1 | 47.2 |
| | | mice (25) | | 20.4 | 23.06 | 49.0 |
| | intratrach. | rats (12) | 0.36-0.41ml water solution | 46.0 | 47.5 | 49.0 |
| | dermal irritation test | rabbits (2) | 4 places (2 scarified), 10 mg/place, covered, + 20 mg into the conjunct. sac (summ: 60 mg) | death after 10 hours (no irritation) | | |
| rabbits (3) | | rabbit 1: 20 mg into the conjunctival sac rabbit 2: 40 mg on the skin (13 mg/kg) rabbit 3: 60 mg on the skin (20 mg/kg?) for 24 hours | rabbit 1: survived 24 hours – no irritation rabbit 2: survived 24 hours – “local reaction” rabbit 3: death after 6 hours – no irritation lethal dose for rabbit was 18-21 mg/kg” | | | |
| Bassendowska et al., (1965) | skin | rats (20) | | | | 60 |
| | | Rabbits (?) | quoted from Bassendowska et al. (1961) | | | 20 |
| Potocar (1985) | skin irritation test | rabbits (6) (2-4 kg bw) | 4x500 mg/animal on 4 3x3 cm gauze pads (2 occlusive, 2 semi-occlusive) 2 patches for 1 hour, 2 for 4 hours (estimated individual doses 500-1000 mg/kg, depending on the weight of the animal) | Evaluation: 1,24,48,72 hr, 7 days after removal of the patch No irritation after 1 h, corrosion after 4 h exposure 3 of 6 animals died – no further data on the time of the deaths | | |

September 2009

19



Annex 2: Occupational inhalation exposure studies for Sodium azide

| Reference | subjects | Previous exposure and complaints | Study | |
|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | exposure measured | medical observations |
| Trout et al. 1996 | 10 production operators + 1 maintenance worker in a highly automated sodium azide production factory Age: 27-42 (mean 33) y. | Max. 3 years of exposure No measurement data. Anamnestic complaints in the previous 6 months: 10/11 had headaches, 9/11 had palpitations, 9/11 had „low” BP at least once. | 10 area samples: NaN ₃ : ND-0.69 mg/m ³ HN ₃ : ND-0.1 ppm 25 Personal Breathing Samples: - 9 samples in blend & pack area: → → Tr – 1.7 mg/m ³ (6 were > 0.3 mg/m ³) - 16 samples in other areas: → → → → ND – 0.23 mg/m ³ | Ambulatory Blood Pressure Monitoring → 1 hypotension: with PBZ 1.7 mg/m ³ 2 mild headaches: (1 with PBZ: trace, 0.31, 0.4 mg/m ³) → 2 mild headaches |
| Rippen et al. 1996 | 65 workers sodium azide production factory | air: NaN ₃ : 0.2-5.87 mg/m ³ Main health complaints: pounding headaches, rapid pulse, perception of lower blood pressure | Area sampling.: NaN ₃ : 1- 7.5 mg/m ³ HN ₃ : 0.45-2.81 ppm 12 Personal Breathing Samples (15 minutes): Group 1: 6 samples: 0.36 – 1.49 mg/m ³ Group 2: 6 samples: 0.01 - 0.15 mg/m ³ Follow up for 9 months: exposure gradually decreased At month 9: area sampling: 0.5 mg/m ³ | 12/65 headaches, 0-3/65 BP changes, no irritation Blood pressure surveillance system: No significant cross-shift changes in blood pressure No significant difference between pre- and post-exposure BP, in any groups, but: pre-exposure BP was significantly lower in Group 1. („may be related to prior exposure relating to activity, work area and individual practices”) 1/65 headache, 2/65 BP changes |

September 2009

20





| Reference | subjects | Previous exposure and complaints | Study | | | | | | | | | | | | | | | | | | | | | | | | | |
|--------------------------------|--------------------------------|----------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|-----------|---------|-------------------|-----|-----|--------------------------------|--|--|----------|----|----|----------|----|----|-------------------------|--|--|-------------|----|---|-----------------------|----|---|
| | | | exposure measured | medical observations | | | | | | | | | | | | | | | | | | | | | | | | |
| Miljouis and Braun 2003 | 41 workers and 42 unexposed | 5 – 30 years "often above the limit value of 0.3 mg/m ³ " | Personal Breathing Samples NaNs: 0.0 - 0.93 mg/m ³ (mean: 0.23) | <table border="0"> <thead> <tr> <th></th> <th>Unexposed</th> <th>Exposed</th> </tr> </thead> <tbody> <tr> <td>Systolic BP mmHg:</td> <td>125</td> <td>131</td> </tr> <tr> <td>Acute symptoms (past 5 days) %</td> <td></td> <td></td> </tr> <tr> <td>Headache</td> <td>85</td> <td>34</td> </tr> <tr> <td>Red eyes</td> <td>85</td> <td>41</td> </tr> <tr> <td colspan="3">Chronic symptoms</td> </tr> <tr> <td>Palpitation</td> <td>12</td> <td>0</td> </tr> <tr> <td>Trembling of the hand</td> <td>15</td> <td>0</td> </tr> </tbody> </table> <p>In 2nd year no chronic symptom. In the 3rd year only palpitation, red eyes and trembling is significant. Number of affected decreased.</p> | | Unexposed | Exposed | Systolic BP mmHg: | 125 | 131 | Acute symptoms (past 5 days) % | | | Headache | 85 | 34 | Red eyes | 85 | 41 | Chronic symptoms | | | Palpitation | 12 | 0 | Trembling of the hand | 15 | 0 |
| | Unexposed | Exposed | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Systolic BP mmHg: | 125 | 131 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Acute symptoms (past 5 days) % | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Headache | 85 | 34 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Red eyes | 85 | 41 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Chronic symptoms | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Palpitation | 12 | 0 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Trembling of the hand | 15 | 0 | | | | | | | | | | | | | | | | | | | | | | | | | | |

